Focused ultrasound for the treatment of bone metastases: effectiveness and feasibility

Anne-Sophie Bertrand 1*, Antoine Iannessi 1, Romain Natale 2, Hubert Beaumont 3, Sebastien Patriti 1, Jiang Xiong-Ying 1, Guillaume Baudin 1 and Antoine Thyss 4

Abstract

Background: To evaluate the effectiveness and feasibility of high-intensity focused ultrasound (HIFU) for the treatment of bone metastases.

Methods: A single-center prospective study was made involving 17 consecutive patients with symptomatic bone metastases. Patients were treated by Focused Ultrasound (FUs) performed with magnetic resonance (MR) guidance. Surgical treatment or radiotherapy treatment was not indicated for patients who underwent FUs. Lesions were located in the appendicular and axial skeleton and consisted of secondary symptomatic lesions. The clinical course of pain was evaluated using the Visual Analog Scale (VAS) before treatment, at 1 week, and at 1 month after treatment and the Oral Morphine Equivalent Daily Dose (OMEDD) was also recorded. We used Wilcoxon signed rank test to assess change in patient pain (R CRAN software V 3.1.1).

Results: We observed a significant decrease in the pain felt by patients between pre-procedure and 1 week post-procedure \( (p = 2.9 \times 10^{-4}) \), and pre-procedure and 1 month post-procedure \( (p = 3.1 \times 10^{-4}) \). The proportion of responders according to the International Bone Metastases Consensus Working Party was: Partial Response 50% (8/16) and Complete Response 37.5% (6/16).

Conclusions: HIFU under MR-guidance seems to be an effective and safe procedure in the treatment of symptomatic bone lesions for patients suffering from metastatic disease. A significant decrease of patient pain was observed.

Trial registration: NCT01091883. Registered 24 March 2010. Level of evidence: Level 3.

Keywords: High-intensity focused ultrasound, Bone neoplasms, Radiotherapy, Pain, Cancer

Background

For 50 years, high-intensity focused ultrasound (HIFU) has been a subject of interest for medical research [1]. HIFU triggers selective tissue necrosis in a very well-defined volume, at a variable distance from the transducer, through heating or cavitation [2]. Its potential as a non-invasive thermal ablation treatment, using real-time imaging (magnetic resonance or ultrasound) for target definition, treatment planning and closed-loop of energy deposition, has been utilized in many settings including the treatment of tumors of the liver, kidney, breast, uterus, pancreas, bones and for the relief of chronic pain of malignant origin [3–5].

Thanks to Magnetic Resonance Imaging (MRI) guidance, real-time thermal feedback of heated zones makes it possible to ablate targeted tissue in real time without damaging normal structures. The precision of the technique and the immediate feedback obtained make it an attractive and safe alternative to surgical or radiation therapy for both benign and malignant tumors [6]. Clinically, the sites accessible for HIFU treatment are limited by the need for a suitable wide and naturally available...
acoustic window [7]. Traditionally, HIFU treatment consists of multiple single focal point sonifications [8, 9]. In volumetric ablation, the focal spot is electronically steered along multiple concentric circles of increasing diameter and is thus more energy-efficient than point by point ablation [10]. In 2011, the Magnetic Resonance-guided Focus Ultrasound (MRgFUS) system received the European Compliance (CE) marking for the treatment of painful bone metastases [4].

Pain due to bone metastases is a common clinical problem in cancer patients [11]. The primary palliative treatment for patients with painful bone metastases is external beam radiation therapy, which achieves effective pain control in around 60–74% of patients [12–14]. More than 40% of patients are still not controlled after a second course of irradiation [15].

Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) has recently emerged as an effective treatment option for painful bone metastases by means of periosteal nerve-ending ablation. However, there exist few articles in the literature related to HIFU for this indication [4, 16–19].

The objective of our study was to describe our experience in the treatment of painful bone metastases using volumetric MR-HIFU ablation and to assess the technical feasibility and safety of the procedure [20].

Materials and methods

Patient population and selection

We present a prospective observational study on 17 consecutive patients (seven males, ten females, mean age: 61 years) suffering from symptomatic bone metastases of the appendicular skeleton. From October 2012 to March 2018, 17 patients with metastatic disease were enrolled. Most patients were suffering from intense inflammatory pain, often associated with mechanical pain and disability for walking or standing, depending on the localization of lesions. The lesions were located in the appendicular skeleton, involving the tibial diaphysis (two cases), femoral diaphysis (two cases), iliac bone (four cases), clavicle (one case), scapula (one case), humerus (one case), and in the axial skeleton, involving the ribs (six cases). All patients had exhausted maximum radiotherapy and analgesic treatment options for their painful bone metastasis.

For inclusion, the pain arising from the lesion had to be self-rated by the patient as ≥5 on an 11-point numeric visual analog scale (VAS) from 0 (no pain) to 10 (worst imaginable pain) [21]. Exclusion criteria were the presence of >3 painful bone metastases, metastases located in the spine, sternum, or skull, contraindications to MR imaging or procedural sedation and analgesia (PSA), presence of a potentially unstable fracture at the site of the lesion, and lesion inaccessibility (≤1 cm distance between the lesion and major nerves, joints, blood vessels or organs) [16].

Pretreatment magnetic resonance imaging (GE Healthcare MRI 1.5 Tesla, Milwaukee, WI) was available for all patients in order to confirm the location of the bone metastases. MR images were evaluated by a radiologist with 10 years’ experience to determine treatment accessibility of the target lesion. Final treatment eligibility was determined in a multidisciplinary setting. The MRI protocol included T1-weighted (T1W) turbo spin echo (TSE) and T2-weighted (T2W) sequences in two orientations and fat-suppressed T1W (SPIR) sequences in two orientations after intravenous administration of gadobutrol, a gadolinium-based contrast agent (Gadovist, Bayer Pharma AG, Berlin, Germany, 0.1 mmol/kg). Approval was obtained from the institutional review board of the Centre Antoine Lacassagne (Nice, France) and written informed consent for the treatment and for the use of their anonymized data for this study was obtained from each patient.

MR-HIFU system ablation

Treatments were performed by an interventional radiologist (with 5 years’ experience) using the MR-HIFU system (ExAblate 2000® MRgFUS system, Insightec, Israel). All procedures were performed under general anesthesia.

Patients were placed in a prone or supine position depending on the lesion location in order to be as close as possible to the transducer for optimal treatment. After identification of the target lesion, sonications were delivered to the patient, with a number of sonications depending on the lesion size, and were adjusted in real time using temperature control at the lesion site (Fig. 1).

The number of sonications delivered in our study ranged between 8 (smallest lesion) and 27 (biggest lesion). The duration of each sonication was 15 s. The average duration of the entire procedure was 2 h.

An immediate post-operative MRI was made at the end of each procedure to evaluate bone metastasis destruction, including T1-weighted fat-suppressed sequence after gadolinium injection. The non-enhanced area after treatment corresponded to the necrotic zone.

Follow-up and response assessment

A prospective follow-up was done, consisting of post-operative evaluations at 1 week and at 1 month to assess the pain felt by the patients. Quantification of pain was made by each subject on an 11-point numeric visual analog scale (VAS) with values from 0 to 10 (where 10 indicates the strongest pain ever experienced and 0 indicates absence of pain) and was supervised by an independent evaluator. Pain evaluation was made specifically on the anatomical site treated by focused
ultrasound (if there were other pain sites, they were not taken into account). A difference in VAS > 2 points was considered a clinically significant result [21]. We also recorded the oral morphine equivalent dose (OMEDD) before treatment and 1 month after treatment.

Partial response was defined as either a ≥ 2-point decrease in VAS at the treated site with no increase in OMEDD or as an OMEDD reduction of 25% or more from baseline without an increase in pain. Complete response was defined as a pain score of 0 at the treated site with stable OMEDD or an increase of 25% or more in OMEDD compared with baseline with the pain score stable or 1 point above baseline [16]. A clinical examination was made before treatment and at 1 week and at 1 month after treatment to evaluate pain evolution.

**Statistical analysis**

The VAS score was measured at these three follow-up examinations. OMEDD was recorded at baseline and after 1 month. Pre-and post-operative VAS and OMEDD were compared using the non-parametric Wilcoxon signed-rank test for paired data. \( P < 0.05 \) was considered statistically significant. Confidence intervals were computed by bootstrapping data. Statistical analyses were performed using R CRAN Software (Version 3.1.1).

**Results**

Data are summarized in Table 1.

**Procedure**

Treatment was technically successful in 17 cases and clinically successful in 16 cases according to VAS (Fig 1). After the MR-HIFU procedure, all lesions were totally or partially destroyed (Figs 2, 3, 4). The feasibility of the procedure was 100% in our study. One case was recorded in which the patient experienced no relief of his pain following the procedure. We observed no immediate or delayed complications, in particular no skin burns.

One patient received no morphine treatment and was not reported by OMEDD.

**Follow-up**

Compared to the onset of treatment, all patients experienced a decrease in pain after 1 week and after 1 month. More than 40% of the cohort reported no pain at all after 1 month.

The average evaluation of pain was 7.53/17 (SD: 1.33) before treatment, 2.29/17 (SD: 1.86) 1 week after treatment, and 1.88/17 (SD: 1.99) 1 month after treatment. Our results show a significant decrease of the pain felt by patients between before the procedure and 1 week following the procedure- \( (p = 2.94.10^{-4}) \), and before the procedure and 1 month following the procedure- \( (p = 2.99.10^{-4}) \).
| Patients | Age (years) | Sex | Primary tumor | Location          | Lesion dimensions (mm) | Soft tissue invasion | Previous Radiotherapy | Results | Technical features |
|----------|-------------|-----|---------------|-------------------|------------------------|---------------------|----------------------|---------|-------------------|
| Nº 1     | 55          | M   | Larynx        | Tibial diaphysis  | 39*38*50               | Yes                 | No                   | 8       | 17               |
| Nº 2     | 54          | F   | Breast        | Femoral neck      | 18*14*28               | No                  | No                   | 9       | 12               |
| Nº 3     | 57          | F   | Lung          | 7th Rib           | 11*7*6                 | No                  | No                   | 8       | 15               |
| Nº 4     | 78          | F   | Breast        | Clavicle          | 44*29*23               | No                  | Yes                  | 7       | 26               |
| Nº 5     | 74          | F   | Endometria    | Ischio-branch     | 50*34*33               | Yes                 | No                   | 10      | 15               |
| Nº 6     | 49          | M   | Kidney        | Scapula           | 15*12*15               | No                  | No                   | 7       | 12               |
| Nº 7     | 89          | M   | Lung          | 6th Rib           | 9*7*5                  | No                  | Yes                  | 7       | 40               |
| Nº 8     | 65          | F   | Lung          | Humerus           | 32*20*27               | No                  | Yes                  | 10      | 10              |
| Nº 9     | 70          | F   | Breast        | 10th rib          | 19*7*7                 | No                  | Yes                  | 6       | 7               |
| Nº 10    | 58          | F   | Lung          | Ilio-branch       | 46*34*24               | Yes                 | Yes                  | 7       | 26               |
| Nº 11    | 64          | F   | Lung          | 8th rib           | 24*13*11               | Yes                 | Yes                  | 8       | 14               |
| Nº 12    | 50          | F   | Breast        | Iliac bone        | 51*24*50               | Yes                 | Yes                  | 8       | 11               |
| Nº 13    | 46          | M   | Kidney        | Tibial diaphysis  | 29*22*47               | Yes                 | Yes                  | 7       | 9                |
| Nº 14    | 47          | M   | Lung          | 4th rib           | 35*18*32               | Yes                 | Yes                  | 7       | 6                |
| Nº 15    | 60          | F   | Breast        | T5 Transverse     | 13*15*20               | No                  | Yes                  | 6       | 12               |
| Nº 16    | 79          | M   | Prostate      | Iliac bone        | 60*40*36               | Yes                 | No                   | 5       | 9                |
| Nº 17    | 48          | M   | Lung          | Femoral diaphysis | 40*26*60               | No                  | No                   | 8       | 16               |

Soft tissue invasion and lesion dimensions given as long axis (transverse) x short axis (transverse) x cranio-caudal dimension (coronal) were measured at pretreatment MRI. Visual Analogic Scale (VAS) before, after 7 days and 1 month were evaluated on a 0–10 scale. Oral Morphine Equivalent Daily Dose (OMEDD) in mg before and after 1 month. Mean acoustic power in Watts. Mean Temperature Monitored in Celsius. Total Delivered Energy in Joules. Treated volume in cubic centimeters using a threshold of 70° in milliliters. *Technical features were collected after treatment inside the HIFU system.
Fig. 2 Patient 6. **a** Sagittal T2-weighted fat-suppressed MR images showing a bone metastasis of the scapula (arrowhead) in hypersignal in front of the transducer (star) before the procedure; **b, c, d** Axial T2, Sagittal and Axial T1-weighted fat-suppressed with contrast MR images after the procedure. The non-enhanced area (hollow arrowhead) is larger than the lesion and is clearly visible after the injection and corresponds to the zone of thermal destruction.

Fig. 3 Patient 5. **a** Axial T2-weighted MR image showing a bone metastasis of the pubic ilio-branch invading adjacent soft tissues (arrow) in front of the transducer (star) before the procedure; **b, c** Axial T2-weighted fat-suppressed and T1-weighted fat-suppressed with contrast MR images showing partial destruction of the lesion after the procedure.
All patients, except patient 2, had decreasing or stable pain between 1 week and 1 month.

Sixteen of the 17 patients were satisfied with their long-lasting result following the procedure and would recommend the intervention to relatives.

Mean OMEDD was respectively 270.6 [78.31; 2293.9] at baseline and 113.75 [44.9; 270.0] at 1 month; no significant difference was observed ($p = 0.18$).

Four patients died several weeks after treatment due to their primary diseases.

**Response analysis**

The proportion of responders according to the International Bone Metastases Consensus Working Party [12] was: Partial Response 50% (8/16) and Complete Response 37.5% (6/16). Overall response was 87.5% [62, 98%].

Progression of pain was observed in 12.5% (2/16) of patients. One patient who experienced pain progression was documented to have not been properly treated for pain. The other patient experiencing pain progression had a VAS score of zero but had a significantly higher OMEDD after 1 month.

**Discussion**

To our knowledge, there are only a few articles in the literature demonstrating the benefit of HIFU with MR guidance for the palliative treatment of bone metastases [16, 22, 23].

Our study shows a significant decrease in patient pain after treatment by HIFU with MRI guidance ($p < 0.05$) at 1 week and at 1 month post procedure. Ten elderly patients were significantly relieved of their pain following the procedure. These patients had several co-morbidities and had exhausted maximum radiotherapeutic and analgesic treatment options for their painful bone metastases. All suffered intense inflammatory pain, often associated with mechanical pain severely decreasing their quality of life. The procedure indication was evaluated very carefully for each patient, as management of symptomatic bone metastases by HIFU depends largely on clinical symptoms and the degree of pain felt by patients. All the patients suffered from a symptomatic bone lesion. The association of bone marrow edema and enhancement of the lesion on the MRI performed before treatment indicated the concordance between clinical symptoms and imaging.
The aim of treatment was to obtain pain palliation and not total lesion destruction. We believe that correct selection of patients is crucial. Indeed, we recorded one patient who experienced no relief of his pain and for whom the effectiveness of the denervation treatment was inconclusive, an observation which argues in favor of a multifaceted etiology of pain.

The feasibility of the HIFU procedure was 100% in our study. All procedures were performed under general anesthesia in order to ensure greater patient comfort since the interventions are lengthy and can be painful during sonications. This procedure can be performed under local anesthesia if necessary in case of contraindication to general anesthesia or, if the patient wishes, by applying good analgesic sedation before the procedure [22].

Hurwitz et al. recently reported the first completed phase III randomized trial investigating MRgFUS in patients with painful bone metastases. They showed a response rate of 64.3% in the MRgFUS arm compared with 20.0% in the placebo arm ($P < .001$) at 3 months [1]. Napoli et al. also showed a slightly higher response rate of 88.9% at 3 months post-treatment [24]. In the recent literature, an international consensus statement recognized MRgFUS as a safe and effective secondary treatment option in painful radiation-refractory bone metastases outside the spine [25]. MRgFUS may be

---

Fig. 5 Patient 13. a, b Axial and Sagittal T2-weighted MR image showing a bone metastasis of the tibial diaphysis in front of the transducer. c Axial T1-weighted fat-suppressed contrast MR image showing thermal destruction and necrosis inside the lesion. d Screen capture during sonication showing the thermal dose deposit (hollow arrowhead) inside the diaphysis. Thermal monitoring is performed using a map (empty star) and a graph (star). Temperature monitoring (star) shows a mean temperature of 91 °C at the end of this sonication.
considered in settings where primary therapeutic modalities—namely, radiotherapy—are contraindicated or are refused by the patient.

These therapeutic techniques appear to be complementary for oncology patients suffering from metastatic disease and can be used in combination for optimal antalgic and therapeutic effectiveness. Further evidence from large randomized control studies is needed to establish MRgFUS as a possible palliative treatment of bone metastases alongside other available therapeutic options [24].

HIFU seems to be a safe and effective treatment procedure as no immediate or delayed complications were observed in our study. To improve pain control during the intervention, patients were treated by direct approach with focused ablation of the periosteum as this is the most highly innervated component of mature bone tissue. In the literature, several possible ablation approaches have been described using HIFU: the “near-field approach” in patients with (partially) intact cortical bone at the targeted lesion, in which treatment cells are initially positioned behind the cortical bone; and the “direct approach” in which treatment cells are positioned on the bone/soft-tissue interface. Although both ablation approaches can induce thermal ablation of the bone/soft-tissue interface, the direct approach requires lower sonication energies compared to the near-field approach, thus minimizing the risk of thermal damage beyond the targeted volume [16]. HIFU treatment also seems to induce a decrease of serum immunosuppressive cytokines such as vascular endothelial growth factor (VEGF) in patients with solid tumors [26].

For optimal effectiveness, the benefit of the HIFU procedure should be estimated in terms of patient pain. However, this can be difficult as pain can be multifactorial in oncology patients. Bone metastases are painful current lesions in oncology patients. HIFU treatment enables us to relieve the pain felt by patients but does not promote bone consolidation, which is often needed in such fragile patients. In these circumstances, the benefits provided by a therapeutic association between different modalities such as cementoplasty, radiotherapy and immunotherapy becomes paramount [11, 27–29].

In MR-HIFU, image guidance is crucial for treatment planning and real-time temperature monitoring as lethal cell damage occurs when temperatures > 55 °C are maintained for longer than 1 s [30]. The measured temperatures represent an approximation of the true temperature of the bone/soft tissue interface, as only temperature differences occurring in aqueous soft-tissue adjacent to the cortical bone can be measured. The method is also sensitive to magnetic field disturbances and artifacts and partial volume may induce a degree of inaccuracy in temperature estimates [31–34] (Fig 5). We observed one patient who presented post-procedure superficial skin irritation, which we treated by anti-inflammatories for 5 days. During the long-term follow-up, four patients in our series died as a result of advanced metastatic disease.

Our study has several limitations. First, we did not compare our results with a control group treated conservatively or with radiation therapy alone. In fact, it was difficult not to treat demanding patients suffering intense pain and to whom we could propose a safe and efficient treatment option. Second, our patient sample was small and the follow-up period was relatively short; long-term clinical outcomes still need to be evaluated. MR-HIFU also has its limitations as the procedure is time-consuming and required general anesthesia in our study. The cost of the technique and its availability are also limiting factors. Indications and benefits of MR-guided HIFU in the treatment of bone metastases should be clearly defined for routine use by interventional radiologists, while new indications for the technique are currently under investigation [35, 36].

In conclusion, MR-guided HIFU seems to be a safe and efficient therapeutic option for patients suffering from bone metastases. The technique can be used alone or in combination with other treatments such as cementoplasty or radiotherapy for palliative treatment in metastatic disease. Patients should be carefully screened for optimal therapeutic effectiveness of the procedure. Future research should include a large well-designed cohort study with longer follow-up, in which patients with persistent metastatic bone pain are treated. The benefits versus risks ratio seems very positive, with a significant decrease in patient pain and the advantages of a non-invasive procedure. This non-invasive interventional radiology technique appears to be a promising additional tool for the management of patients in oncology.

Abbreviations
FUs: Focused Ultrasound; HIFU: High-Intensity Focused Ultrasound; MR: Magnetic Resonance; MRI: Magnetic Resonance Imaging; OMEDD: Oral Morphine Equivalent Daily Dose; VAS: Visual Analog Scale

Acknowledgements
Not applicable.

Funding
No funding was received for this study.

Availability of data and materials
Please contact author for data requests.

Authors’ contributions
Dr. AI and Dr. ASB conceived the study, participated in its design and drafted the manuscript. Mr. HB participated in the design of the study and performed the statistical analysis. Mr. SP collected the data and images. Dr. RN, Dr. JXY, Dr. GB and Pr AT participated in the coordination of the study and in reviewing the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by our institutional review board: CPP (Comité de Protection des Personnes Sud Méditerranée V, reference number: 12.061). Written informed consent for the treatment in this study was obtained for each patient.

Consent for publication
All patients included in the trial gave their consent for the use of their anonymized data and for publication.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Department of Interventional Radiology, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrase, 06100 NICE, France.
2. Department of Radiotherapy, Centre de Lutte contre le Cancer Antoine Lacassagne, 33 Avenue de Valombrase, 06100 NICE, France.
3. Department of Statistics, University of Nice Sophia Antipolis, 28 Avenue Valrose, 06000 NICE, France.
4. Department of Oncology, Centre de Lutte anti-Cancer Antoine Lacassagne, 33 Avenue de Valombrase, 06100 NICE, France.

Received: 9 June 2018 Accepted: 1 November 2018
Published online: 30 November 2018

References
1. Hurwitz MD, Ghanouni P, Kanaev SV, Ioffe D, Gianfelice D, Fennelly FM, et al. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014;106(5):du082.
2. Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: surgery of the future? Br J Radiol. 2003;76:590–9.
3. Al-Bataineh O, Jenne J, Huber P. Clinical and future applications of high intensity focused ultrasound in cancer. Cancer Treat Rev. 2012;38:346–53.
4. Huisman M, van den Bosch MA. MR-guided high-intensity focused ultrasound for noninvasive cancer treatment. Cancer Imaging. 2011;11:1516–6.
5. Dababou S, Marrocchio C, Rosenberg J, Bitton R, Pauly KB, Napoli A, et al. A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound. J Thor Ultrasound. 2017;5:9.
6. Jolesz FA. MR-guided focused ultrasound surgery. Annu Rev Med. 2009;60:417–30.
7. Hill CR, ter Haar GR. Review article: high intensity focused ultrasound—potential for cancer treatment. Br J Radiol. 1995;68:129–33.
8. Elias WJ, Huss D, Voss T, Loomba J, Khaled M, Ghanouni P, Lovey G, et al. International consensus on use of focused ultrasound for painful bone metastases: current status and future directions. Int J Hyperth. 2015;31:251–9.
9. Zhou Q, Zhu XQ, Zhang J, Xu ZL, Lu P, Wu F. Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment. Ultrason Med Biol. 2008;34:81–7.
10. Bedard G, Chow E. The failures and challenges of bone metastases research in radiation oncology. J Bone Oncol. 2013;2:84–8.
11. Mawrogenis AF, Angelini A, Vortis C, Pala E, Calabro T, Papageorgopoulos PJ, et al. Modern palliative treatments for metastatic bone disease: awareness of advantages, disadvantages, and guidance. Clin J Pain. 2016;32:337–50.
12. Ringi KI, Panizza M, van Falck C. Thermoablation of bone tumors. Rofo. 2016;188:359–60.
13. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10:787–800.
14. Reike V, Butts Pauly K, MR thermometry. J Magn Reson Imaging. 2008;27:376–90.
15. de Senneville BD, Mougenot C, Quesin B, Dragouin I, Grenier N, Moenner CT. MR thermometry for monitoring tumor ablation. Eur Radiol. 2007;17:2401–10.
16. Schlesinger D, Benedict S, Diederich C, Greifow W, Kilbanov A, Larner J. MR-guided focused ultrasound surgery, present and future. Med Phys. 2013;40:080901.
17. Huisman M, Huisman M, Nijenhuis RJ, van den Bosch MA, Viergever MA, Moenner CT, et al. Quality of MR thermometry during palliative MR-guided high-intensity focused ultrasound (MR-HIFU) treatment of bone metastases. J Ther Ultrasound. 2015;3:5.
18. Karakitsios I, Mlinic S, Saliev T, Melzer A. Feasibility study of pre-clinical Thiel embalmed human cadaver for MR-guided focused ultrasound of the spine. Minim Invasive Ther Allied Technol. 2016;25:154–61.
19. Trumm CG, Napoli A, Peller M, Clevert DA, Stahl R, Reiser M, et al. MR-guided focused ultrasound. Current and future applications. Radiologe. 2013;53:200–8.